NEURONETICS INC (STIM)

US64131A1051 - Common Stock

1.57  +0.08 (+5.37%)

After market: 1.5997 +0.03 (+1.89%)

Fundamental Rating

2

Overall STIM gets a fundamental rating of 2 out of 10. We evaluated STIM against 187 industry peers in the Health Care Equipment & Supplies industry. STIM may be in some trouble as it scores bad on both profitability and health. STIM is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

STIM had negative earnings in the past year.
STIM had a negative operating cash flow in the past year.
In the past 5 years STIM always reported negative net income.
STIM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

STIM has a worse Return On Assets (-49.14%) than 66.67% of its industry peers.
STIM has a Return On Equity of -388.26%. This is amonst the worse of the industry: STIM underperforms 84.41% of its industry peers.
Industry RankSector Rank
ROA -49.14%
ROE -388.26%
ROIC N/A
ROA(3y)-26.65%
ROA(5y)-28.76%
ROE(3y)-63.33%
ROE(5y)-71.65%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 75.70%, STIM belongs to the top of the industry, outperforming 87.10% of the companies in the same industry.
In the last couple of years the Gross Margin of STIM has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for STIM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.05%

More info and screens

3

2. Health

2.1 Basic Checks

STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STIM has been increased compared to 1 year ago.
Compared to 5 years ago, STIM has more shares outstanding
The debt/assets ratio for STIM is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -6.57, we must say that STIM is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.57, STIM is not doing good in the industry: 74.73% of the companies in the same industry are doing better.
A Debt/Equity ratio of 4.90 is on the high side and indicates that STIM has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 4.90, STIM is doing worse than 88.17% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 4.9
Debt/FCF N/A
Altman-Z -6.57
ROIC/WACCN/A
WACC10.01%

2.3 Liquidity

STIM has a Current Ratio of 3.16. This indicates that STIM is financially healthy and has no problem in meeting its short term obligations.
STIM has a Current ratio (3.16) which is in line with its industry peers.
STIM has a Quick Ratio of 2.87. This indicates that STIM is financially healthy and has no problem in meeting its short term obligations.
STIM has a better Quick ratio (2.87) than 62.37% of its industry peers.
Industry RankSector Rank
Current Ratio 3.16
Quick Ratio 2.87

More info and screens

4

3. Growth

3.1 Past

STIM shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.24%.
Looking at the last year, STIM shows a small growth in Revenue. The Revenue has grown by 5.03% in the last year.
The Revenue has been growing slightly by 6.21% on average over the past years.
EPS 1Y (TTM)-4.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)5.03%
Revenue growth 3Y13.16%
Revenue growth 5Y6.21%
Sales Q2Q%3.61%

3.2 Future

Based on estimates for the next years, STIM will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.49% on average per year.
STIM is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.16% yearly.
EPS Next Y-21.38%
EPS Next 2Y14.75%
EPS Next 3Y15.06%
EPS Next 5Y18.49%
Revenue Next Year0.61%
Revenue Next 2Y4.22%
Revenue Next 3Y6.83%
Revenue Next 5Y10.16%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

STIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STIM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as STIM's earnings are expected to grow with 15.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.75%
EPS Next 3Y15.06%

More info and screens

0

5. Dividend

5.1 Amount

STIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEURONETICS INC

NASDAQ:STIM (1/6/2025, 4:17:28 PM)

After market: 1.5997 +0.03 (+1.89%)

1.57

+0.08 (+5.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)01-06 2025-01-06/amc
Inst Owners54.02%
Inst Owner Change0%
Ins Owners6.35%
Ins Owner Change4.75%
Market Cap87.37M
Analysts80
Price Target2.72 (73.25%)
Short Float %0.93%
Short Ratio1.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-53.69%
Min EPS beat(2)-87.55%
Max EPS beat(2)-19.83%
EPS beat(4)2
Avg EPS beat(4)-16.02%
Min EPS beat(4)-87.55%
Max EPS beat(4)28.7%
EPS beat(8)5
Avg EPS beat(8)1.29%
EPS beat(12)8
Avg EPS beat(12)5.15%
EPS beat(16)10
Avg EPS beat(16)4.2%
Revenue beat(2)0
Avg Revenue beat(2)-9.28%
Min Revenue beat(2)-13.51%
Max Revenue beat(2)-5.05%
Revenue beat(4)1
Avg Revenue beat(4)-4.63%
Min Revenue beat(4)-13.51%
Max Revenue beat(4)0.33%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)7
Avg Revenue beat(12)0.3%
Revenue beat(16)9
Avg Revenue beat(16)0.27%
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-59.14%
EPS NY rev (1m)0%
EPS NY rev (3m)-45.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-17.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.2
P/FCF N/A
P/OCF N/A
P/B 9.31
P/tB 9.31
EV/EBITDA N/A
EPS(TTM)-1.23
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS1.31
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.14%
ROE -388.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.7%
FCFM N/A
ROA(3y)-26.65%
ROA(5y)-28.76%
ROE(3y)-63.33%
ROE(5y)-71.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.05%
F-Score3
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 4.9
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 105.77%
Cap/Sales 3.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.16
Quick Ratio 2.87
Altman-Z -6.57
F-Score3
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)179.33%
Cap/Depr(5y)138.27%
Cap/Sales(3y)4.19%
Cap/Sales(5y)3.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y-21.38%
EPS Next 2Y14.75%
EPS Next 3Y15.06%
EPS Next 5Y18.49%
Revenue 1Y (TTM)5.03%
Revenue growth 3Y13.16%
Revenue growth 5Y6.21%
Sales Q2Q%3.61%
Revenue Next Year0.61%
Revenue Next 2Y4.22%
Revenue Next 3Y6.83%
Revenue Next 5Y10.16%
EBIT growth 1Y13.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.23%
EBIT Next 3Y25.65%
EBIT Next 5Y25.07%
FCF growth 1Y36.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.97%
OCF growth 3YN/A
OCF growth 5YN/A